文献速递前列腺癌

临床局限性前列腺癌接受外照射放疗后治疗后活检阳性的长期意义

Long-Term Implications of a Positive Posttreatment Biopsy in Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.
PubMed 文献 · J Urol · 2019-01-01

研究纳入382例临床局限性前列腺癌接受外照射放疗后行治疗后活检的患者,中位随访9年。活检阳性率为30%,严重治疗效应为22%,阴性为48%。阳性活检者15年前列腺特异性抗原复发率为79%,远距离转移风险高2.6倍,前列腺癌特异性死亡风险为阴性及严重治疗效应者的2倍(HR 2.00,p=0.022)。

要点

  • 治疗后活检阳性率为30%,严重治疗效应为22%,阴性为48%。
  • 阳性活检者15年PSA复发率为79%,阴性者为34%,严重治疗效应者为36%(p<0.001)。
  • 阳性活检者远距离转移风险高2.6倍(p<0.001),前列腺癌特异性死亡风险为阴性及严重治疗效应者的2倍(HR 2.00,p=0.022)。

核心结论

  • 外照射放疗后治疗后活检阳性与远距离转移和前列腺癌相关死亡风险升高相关。
  • 严重治疗效应分类的活检生物学特征更接近阴性活检而非阳性活检。
  • 未接受雄激素剥夺治疗或高危疾病者治疗后活检阳性更常见。

研究设计与样本

  • 382例临床局限性前列腺癌患者接受外照射放疗后行治疗后活检。
  • 治疗后活检分为阳性(前列腺腺癌无典型放疗诱导改变)、阴性(无癌证据)或腺癌伴严重治疗效应。
  • 幸存者中位随访9年,采用竞争风险回归评估预后预测因素与病因特异性死亡、远距离转移和前列腺特异性抗原失败的关系。

主要发现

  • 阳性活检、治疗效应和阴性活检的患病率分别为30%、22%和48%。
  • 未接受雄激素剥夺治疗和高危疾病分别与治疗后活检阳性的比值增加2.6倍和1.8倍相关。
  • 阴性、严重治疗效应和阳性治疗后活检对应的15年前列腺特异性抗原复发率分别为34%、36%和79%(p<0.001)。
  • 控制已知预测因素后,阳性活检者远距离转移风险高2.6倍(p<0.001)。
  • 阳性活检者病因特异性死亡风险为阴性及严重治疗效应活检结局者的2倍(HR 2.00,p=0.022)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We determined the prognostic importance of a positive posttreatment biopsy after prostate radiotherapy. MATERIALS AND METHODS: A total of 382 patients underwent a posttreatment biopsy after external beam radiotherapy for clinically localized prostate cancer. Posttreatment biopsies were classified as positive (prostatic adenocarcinoma without typical radiation induced changes), negative (no evidence of carcinoma) or adenocarcinoma with a severe treatment effect. Median followup in survivors was 9 years. Competing risks regression was used to assess relationships between prognostic predictors and cause specific mortality, distant metastasis and prostate specific antigen failure. RESULTS: The prevalence of positive biopsy, treatment effect and negative biopsy was 30%, 22% and 48%, respectively. Androgen deprivation therapy omission and high risk disease were associated with a 2.6 and 1.8-fold increase, respectively, in the odds of positive posttreatment biopsy. The 15-year PSA relapse rate associated with negative, severe treatment effect and positive posttreatment biopsies was 34%, 36% and 79%, respectively (p <0.001). After controlling for known predictors the risk of distant metastasis was 2.6-fold higher in patients with a positive biopsy (p <0.001) and cause specific mortality was twice as high in patients with a positive biopsy compared to those with negative and severe treatment effect biopsy outcomes (HR 2.00, p = 0.022). CONCLUSIONS: A positive posttreatment biopsy after external beam radiotherapy was associated with a higher risk of distant metastasis and prostate cancer related death. Patients with severe treatment effect classified biopsies have biological characteristics more like patients with a negative biopsy than a positive biopsy. Posttreatment biopsies were more often positive in the setting of external beam radiotherapy alone without androgen deprivation therapy or in the presence of high risk disease.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Zelefsky MJ, Goldman DA, Reuter V, et al. Long-Term Implications of a Positive Posttreatment Biopsy in Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer. J Urol. 2019. PMID: 30741847. doi:10.1097/JU.0000000000000110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。